Please login to the form below

Not currently logged in
Email:
Password:

Sigurdur Olafsson becomes CEO of Hikma

And Said Darwazah is appointed as executive chairman

Sigurdur OlafssonHikma pharmaceuticals has appointed Sigurdur Olafsson as its new chief executive officer, a role that will also see him join the board as an executive director.

Olafsson has over 25 years of pharmaceutical experience, bringing commercial and operational capabilities to his new role.

He was most recently president and chief executive officer of the Global Generic Medicines Group of Teva Pharmaceuticals, a position he held from 2014 to 2016.

His career has also seen him serve in various capacities for Actavis, Pfizer and Omega Farma.

Olafsson said: “I am looking forward to leading the Hikma team, building on the strong legacy the business has established, particularly in the US and MENA and I believe we have the power do deliver substantial value to our customers, employees, investors and the wider community.”

As chief executive officer, Olafsson will take responsibility for the effective development and execution of Hikma’s corporate strategy, focusing on opportunities to accelerate growth of the global business.

Said Darwazah, Hikma’s recently appointed executive chairman, said: “ We are delighted that Sigurdur is joining Hikma as out new CEO.

“He brings a wealth of pharmaceutical and leadership experience and we are confident that his deep sector knowledge, paired with his proven ability to drive growth, will help us achieve our ambitions for the business.”

As executive chairman, Darwazah will lead the board of directors and he will oversee and engage with the chief executive in setting and delivering the strategic vision for the company.

26th February 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics